IDEX Biometrics ASA

As of June 30, 2026, IDEX Biometrics ASA carries a market capitalization of 55.04M, placing it among publicly traded companies globally. Its enterprise value stands at 52.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IDEX Biometrics ASA's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, IDEX Biometrics ASA has 77.31M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 110.97, and the price-to-book ratio stands at 7.77.

These figures are as of June 30, 2026. The EV/Sales ratio of 145.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 52.52M versus a market cap of 55.04M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, IDEX Biometrics ASA maintains a current ratio of 4.51, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is - -, indicating a certain level of leverage, while an interest coverage ratio of -4.48 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, IDEX Biometrics ASA posted a negative return on equity (ROE) of -191.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -91.39, reflecting losses generated across the asset base. The company generates approximately 12,376.77 in revenue per employee across its workforce of 29.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.54 indicates how many times IDEX Biometrics ASA sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, IDEX Biometrics ASA's stock has gained approximately 158.43% over the past 52 weeks. The 50-day moving average sits at 0.62, while the 200-day moving average is 0.70.

Over the twelve months ended June 30, 2026, IDEX Biometrics ASA generated 362,020.62 in revenue and converted that into -7.57M in net income, yielding earnings per share of -0.13. EBITDA reached -7.78M, while operating income came in at -8.02M.

As of June 30, 2026, IDEX Biometrics ASA holds 2.52M in cash and equivalents against - - in total debt, resulting in a net debt position of -2.52M. Total book value stands at 7.08M, with working capital of 6.62M providing operational flexibility.

IDEX Biometrics ASA produced -8.75M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -41,238.48 in capital expenditures, free cash flow totaled -8.79M - equivalent to -0.16 per share.

Over the twelve months ended June 30, 2026, IDEX Biometrics ASA posted a gross margin of -667.28, reflecting its pricing power and cost economics. The operating margin of -2,215.17 and net profit margin of -2,090.07 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -21.88: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.07, meaning IDEX Biometrics ASA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

IDEX Biometrics ASA's most recent stock split took place on July 7, 2025 with a 100:1 split ratio.